key: cord-0938186-fdhvtz7g authors: Bulfamante, G. P.; Perrucci, G. L.; Falleni, M.; Sommariva, E.; Tosi, D.; Martinelli, C.; Songia, P.; Poggio, P.; Carugo, S.; Pompilio, G. title: Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement date: 2020-08-26 journal: nan DOI: 10.1101/2020.08.24.20170175 sha: 5b237367ba5ce3a2031bc8fdcc050e25507f1883 doc_id: 938186 cord_uid: fdhvtz7g Background - Cardiovascular complication in patients affected by novel Coronavirus respiratory disease (COVID-19) are increasingly recognized. However, although a cardiac tropism of SARS-CoV-2 for inflammatory cells in autopsy heart samples of COVID-19 patients has been reported, the presence of the virus in cardiomyocytes has not been documented yet. Methods - We investigated for SARS-CoV-2 presence in heart tissue autopsies of 6 consecutive COVID-19 patients deceased for respiratory failure showing no signs of cardiac involvement and with no history of heart disease. Cardiac autopsy samples were analysed by digital PCR, Western blot, immunohistochemistry, immunofluorescence, RNAScope, and transmission electron microscopy assays. Results - The presence of SARS-CoV-2 into cardiomyocytes was invariably detected. A variable pattern of cardiomyocytes injury was observed, spanning from the absence of cell death and subcellular alterations hallmarks to the intracellular oedema and sarcomere ruptures. In addition, we found active viral transcription in cardiomyocytes, by detecting both sense and antisense SARS-CoV-2 spike RNA. Conclusions - In this analysis of autopsy cases, the presence of SARS-CoV-2 into cardiomyocytes, determining variable patterns of intracellular involvement, has been documented. All these findings suggest the need of a cardiologic surveillance even in survived COVID-19 patients not displaying a cardiac phenotype, in order to monitor potential long-term cardiac sequelae. disease (COVID-19) 1 is still increasing worldwide. Beside SARS-CoV-2 virus lung tropism causing an atypical severe acute respiratory distress syndrome (ARDS), 2 evidence is now available about the involvement in COVID-19 patients of several other organs, including the cardiovascular system. About 20-40% of hospitalized patients manifest a wide spectrum of symptoms related to heart injury, ranging from mild chest discomfort, palpitations, arrhythmias to cardiogenic shock and fulminant heart failure. 3 Furthermore, myocardial injury has been documented in more than 50% of deceased patients 4 with up to 7% of COVID-19 related deaths linked to myocarditis. 5 To date, it is not clearly understood whether the cause of the cardiovascular involvement of COVID-19 patients is due to SARS-CoV-2 direct cell damage or is rather secondary to the excessive immune system reaction. The systemic hyper-inflammatory status may act as a trigger for an aberrant host immune response mediated by natural killer (NK) cells, macrophages, and Tlymphocytes. 6 Inflammation-mediated leucocyte adhesion molecules on endothelium may cause coronary dysfunction with ischemia 7 or acute coronary syndrome. 8 Alternatively, ARDS-induced hypoxia associated with systemic sepsis, fever, and hypotension may lead to myocardial injury 7, 9 due to the oxygen supply and demand imbalance. On the other hand, SARS-CoV-2 has been found in vascular endothelial cells of patients affected by endotheliitis 10 as well as in cardiac macrophages of COVID-19 patients with cardiogenic shock and myocarditis. 11,12 Moreover, viral RNA has been previously reported in COVID-19 patients' whole heart tissue, 13,14 regardless of a cardiac phenotype. 15, 16 The cell invasion mechanism of SARS-CoV-2 is mainly mediated by ACE2 receptor 17 , which is highly expressed by several cardiac cell types, such as pericytes, 18 cardiomyocytes, 19 and endothelial cells 10, 20 . Nonetheless, immunohistochemistry for viral antigen detection in cardiomyocytes has never been shown. 21, 22 Here, we present, for the first time, data on SARS-CoV-2 sense and antisense RNA as well as viral protein presence in cardiomyocytes of autopsy heart samples of 6 patients deceased for COVID-19dependent severe respiratory insufficiency. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The raw data are available in Zenodo, at https://dx.doi.org/10.5281/zenodo.3974891. Autopsies of 6 consecutive non selected patients involved in this study, 5 males and 1 female, aged 54-69 years (average age: 59.5 ± 5.9 years) with a diagnosis of COVID-19, confirmed by CT analysis (Suppl. Fig. 1 ) and polymerase chain reaction (PCR), were performed in a BSL3 equipped autopsy room at the Unit of Pathology of "ASST Santi Paolo e Carlo" of Milan. Examiners worn clad in all necessary DPIs. Examiners followed the recently published guidelines for performing autopsies and samples with suspected COVID-19 (SIAPEC-IAP). 23 The autopsy examination was performed as soon as possible, by following the recently published recommendations. The period from death to post-mortem autopsy ranged from 1 to 2 hours, documented instrumentally with a continuous and flat ECG for 20 minutes. All patients had no clinical signs of heart damage and died for SARS-CoV-2-dependent respiratory failure after hospitalization in the Intensive Care Unit. In Table 1 clinical characteristics of all 6 patients involved in this study have been summarized. The autopsy included complete histopathology and virology evaluation. Clinical records were checked for clinical conditions at hospitalization. Tissue samples for RNA were stored in RNAlater (Sigma-Aldrich, Saint Louis, MO, USA). Then, RNA was extracted from tissues by using TRIzol (ThermoFischer Scientific, Waltham, MA, USA) and Hybrid-R columns (GeneAll Biotechnology, Seoul, Korea), following the manufacturer's instructions. The RNA quantification was performed by spectrophotometer ND-1000 (NanoDrop®, EuroClone, Pero, Milan, Italy). For viral RNA quantification in myocardial specimens, a one-step chip-based digital PCR was performed on a QuantStudio 3D Digital PCR System platform composed by the QuantStudio 3D Instrument, the Dual Flat Block GeneAmp PCR System 9700 and the QuantStudio 3D Digital PCR Chip The membranes were incubated with peroxidase-conjugated secondary antibodies (GE Healthcare, Chicago, IL, USA) for 1 hour. Signals were visualized using the Western blotting chemiluminescence substrate LiteUP (EuroClone, Pero, Milan, Italy). Images were acquired with the ChemiDoc system (Bio-Rad Laboratories, Hercules, CA, USA). Hearts samples were mapped as follows: full thickness samples from ventricles, atri (2 for each side), and 2 from interventricular septum. Specimens were routinely fixed in 10% buffered formaldehyde for 48 hours as recommended 23 and then 3-µm sections were processed for histopathologic evaluation as well as for immunostainings. Immunohistochemistry was performed with the automatic immunostainer DAKO OMNIS (DAKO, Glostrup, Denmark), using staining kit with magenta and brown chromogens, routinely applied in our laboratory. The magenta staining was adopted to avoid misinterpretation with lipofuscin granularity typical of cardiomyocyte cytoplasm. The histochemistry with phosphotungstic acid haematoxylin (PTAH) was performed according to manufacturer's protocol (BioOptica, Milan, Italy). Primary antibodies adopted for immunohistochemistry and immunofluorescence were specific for SARS-CoV-2 nucleoprotein (Sino Biological, Düsseldorfer, Germany), SARS-CoV-2 spike protein (GeneTex, Irvine, CA, USA), and α -SARC (AbCam, Cambridge, UK). As for SARS-CoV-2 nucleoprotein, samples from lungs of patients under study, with immunoreactivity in reactive pneumocytes, macrophages and epithelial respiratory cells were used as controls. Negative controls were also included in the study by omitting the primary antibody. For all the stainings, archival heart and lung tissue samples from patients dead for diseases other than COVID-19 and cardiologic causes were used as controls (Healthy Control). Immunofluorescence images and analyses were performed by using a Zeiss LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany). Except for immunofluorescence, all slides were digitalized with the NanoZoomer S360 Digital slide scanner C13220-01 (Hamamatsu Photonics, Milan, Italy). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20170175 doi: medRxiv preprint The RNAScope assays (ACD, Bio-technè, Minneapolis, MN, USA) was performed on 3-µm formalin-fixed paraffin-embedded sections, following Wang et al. published method 24 , by using specific probes for sense and antisense SARS-CoV-2 RNA spike sequences. Nuclei were counterstained with haematoxylin and the images were acquired by AxioImager microscope (Carl Zeiss, Oberkochen, Germany). DNA fragmentation associated to necrosis and/or apoptosis was visualized using a terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) detection kit (Roche, Mannheim, Germany). At last, nuclei were counterstained with Hoechst (ThermoFischer Scientific, Waltham, MA, USA) and images were acquired by ApoTomeII microscope (Carl Zeiss, Oberkochen, Germany). Cardiac tissue samples for ultrastructural analysis were fixed in 2.5% glutaraldehyde in 0.13 M phosphate buffer pH 7.2-7.4 for 2 hours, post-fixed in 1% osmium tetroxide, dehydrated through graded ethanol and propylen oxide, and embedded in epoxy resin. Ultrathin sections of 50 to 60 nm not counterstained were observed with transmission electron microscope Leo 912ab (Carl Zeiss, Oberkochen, Germany). Approval was not required (GU n. 72 26/03/2012, page 49). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20170175 doi: medRxiv preprint The patient features reported in Table 1 highlight that all the subjects died for respiratory failure. disease. Only 1 out of 6 presented a slightly altered cardiac clinical profile, due to a mild hypertrophic LV, likely secondary to hypertension, occurring before the hospitalization for COVID-19 disease. Importantly, all patients did not show alterations of ultrasensitive Troponin I; 2 out of 6 were hypertensive; 2 out of 6 showed hypercholesterolemia, none was diabetic, and 1 presented thyroid dysfunction. All the 6 patients were assisted by mechanical ventilation in Intensive Care Unit for a period ranging from 6 to 21 days. Concerning autopsy details, hearts ranged in size 410-750 grams (normal: 365 ± 71 grams), with cardiomegaly related to right ventricle dilation, due to lung overload. On cut surface, cardiac tissue was firm, brown, free of lesions, with some delicate areas of myocardiosclerosis in 1 out of 6 patient left ventricles; the coronary system was unremarkable, with no significant stenosis nor thrombosis. We initially confirmed SARS-CoV-2 cardiac tropism in these patients, by examining with chip-based digital PCR the presence of viral RNA in total RNA extracts from heart tissue samples. Viral RNA was found in all COVID-19 heart specimens, but not in the healthy control. The number of copies of SARS-CoV-2 RNA molecules ranged from 4.44 to 5.33 log10(copies/mL) (Figure 1a) . A Western blot analysis of total protein cardiac autopsy specimen lysates confirmed that the wellknown viral gate of host cells ACE2 receptor 17 was expressed in the cardiac tissue 20 . Similar levels of expression were found in different cardiac districts and, of note, independently on COVID-19. Furthermore, we showed, for the first time, that SARS-CoV-2 viral proteins are detectable in COVID-19 patient hearts, while no traces have been found in the healthy control. In detail, nucleoprotein and spike protein were expressed at different levels in the analysed patients (Figure 1b) , raising the hypothesis that the viral genome is actively transcribed into cardiomyocytes. The light microscopy analyses performed firstly allowed us to define all COVID-19 cases as similar by microscopic aspects. In details, the immunohistochemical analyses confirmed positivity for COVID-19 in left ventricular cardiac samples for SARS-CoV-2 nucleoprotein and spike protein (Figure 2a, b) . Of note, viral proteins were found within cardiomyocytes cell body, and more specifically, in cytosolic are of lipofuscin (Suppl . Fig. 2a) . This finding was confirmed by immunofluorescence co-staining of viral nucleoprotein with α SARC-positive cells (Figure 2c) . In order to determine the presence of SARS-CoV-2 as transcriptionally active virus into cardiomyocytes, we performed the RNAScope assay (Figure 3) . 24 In detail, this in situ hybridization was performed by use of two different probes, recognising the spike protein RNA, sense (Figure 3a) and antisense (Figure 3b) , allowing distinction of the viral RNA genome from its transcript. Signals were obtained . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20170175 doi: medRxiv preprint with both probes in cardiomyocytes of COVID-19 patients only, but the most abundant staining resulted from the probe detecting the actively transcribed virus (Figure 3b) . In Figure 4 , the immunohistochemistry for SARS-CoV-2 nucleoprotein and PTAH staining, performed on consecutive heart sections, highlighted several microscopic scenarios. Not all the cardiomyocytes contain the virus, and among those positive for the viral nucleoprotein we found living and unaltered cells (Figure 4a ). Nonetheless, we appreciated, through PTAH staining, isolated or grouped cardiomyocytes showing atypical degenerative aspects, such as increased cell volumes with intracellular oedema, together with rarefied, disarranged, disrupted, and plurifocally clumped myofibrils (Figure 4b) . In order to investigate whether these interesting features, concerning cardiac cell alterations, may be linked to apoptotic/necrotic processes activation, we performed TUNEL assay on all the subject samples and we detected no cell death signs, except for the peripheral sample regions (Figure 4c, d) . Vascular modifications were unremarkable; no endothelial viral cytopathic effects nor endotheliitis was here documented. Furthermore, a low grade of inflammatory infiltrates was observed in cardiac tissue, especially in sub-pericardiac regions without a specific distribution (Suppl. Fig. 2b) . Sporadic interstitial macrophages displayed a strong immunoreactivity for SARS-CoV-2 nucleoprotein (Suppl. Fig. 2c) . The investigation by electron microscopy confirmed the previously obtained evidence on the SARS-CoV-2 presence in cardiomyocytes. Indeed, single and/or grouped spherical particles about ~130 nm in diameter, with electron dense periphery characterized by crown-shaped small external projections and a morphology compatible to SARS-CoV-2 were clearly visible in the intracellular space between sarcomeres and sarcolemma of cardiomyocytes (arrows, Figure 5a, b) . As for immunohistochemistry and histology assays, the cardiomyocyte phenotype is not univocal: while some cardiomyocyte hosting SARS-CoV-2 did not present any evident abnormality in terms of cellular structures, other cardiac cells presented peculiar degenerative features, such as excessive intracellular area between sarcolemma and sarcomere structure (Figure 5c, d) and abnormal, disrupted and clumped myofibrils (Figure 5e, f) . Regarding the former alteration, this cardiomyocyte swelling (Figure 5c , hashtag) may microscopically explain the cardiac oedema, previously observed in histological examinations. Noteworthy, the sarcomere rupture occurs in co-localization of SARS-CoV-2 viral particle (Figure 5f , hashtag). Although the microscopy investigation was compatible with cardiomyocyte damage, it is important to highlight that, at ultrastructural level, the sarcolemma and mitochondria resulted unaltered and structurally undamaged (Figure 5a, c, e, asterisks) , thus not suggestive of cardiomyocyte death. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. Our crucial study specifically suggest the need to redefine post-discharge surveillance guidelines for surviving COVID-19 patients' follow-up even in the absence of overt cardiac phenotype, since the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20170175 doi: medRxiv preprint cardiovascular long-term outcome of COVID-19 patients may mirror SARS patients, who developed cardiovascular abnormalities in 40% of recovered cases in a 12-years-long follow-up period. 5 This study has limitations inherent to the limited number of patients' autopsies included. However, our findings clearly and consistently show that SARS-CoV-2 is present and active in cardiomyocytes of our COVID-19 patients. Accordingly, we deliberately did show any statistical analysis, since we observed a complete absence of SARS-CoV-2 signal in healthy control samples included in the experiments. For all these reason, future studies will be necessary to confirm our data which are, at present, unprecedented. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20170175 doi: medRxiv preprint Covid-19 and the cardiovascular system Covid-19 does not lead to a "typical" acute respiratory distress syndrome. American journal of respiratory and critical care medicine Covid-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (covid-19) prognosis and recovery. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese Covid-19 and the heart: An update for clinicians Pathological findings of covid-19 associated with acute respiratory distress syndrome The heart in covid19: Primary target or secondary bystander? JACC. Basic to translational science Association of coronavirus disease 2019 (covid-19) with myocardial injury and mortality Acute infection and myocardial infarction Endothelial cell infection and endotheliitis in covid-19 Detection of viral sars-cov-2 genomes and histopathological changes in endomyocardial biopsies Autopsy findings and venous thromboembolism in patients with covid-19 Multiorgan and renal tropism of sars-cov-2. The New England journal of medicine Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor The ace2 expression in human heart indicates new potential mechanism of heart injury among patients infected with sars-cov-2 Regulation of ace2 in cardiac myocytes and fibroblasts Effect of angiotensin-converting enzyme inhibition and angiotensin ii receptor blockers on cardiac angiotensin-converting enzyme 2 Pathology and pathogenesis of sars-cov-2 associated with fatal coronavirus disease, united states. Emerging infectious diseases Rnascope: A novel in situ rna analysis platform for formalin-fixed, paraffin-embedded tissues Cardiac involvement in a patient with coronavirus disease 2019 (covid-19)